HIMS · Hims & Hers Health Inc.
AI read · Neutral
The AI's read
HIMS reported mixed Q2: revenue beat $753.21M, subscribers rose to nearly 2.9M, and the company raised FY26 revenue guidance. But losses widened to $0.37 a share, well worse than the expected $0.03, and costs tied to GLP-1 and international expansion hit margins. The market knocked the stock about 6% and RSI sits at 23.82, so some downside is already reflected in price. That said, the size of the loss surprises and margin pressure create real re-rate risk for the multiple. We lean BEARISH. The miss is company-specific and can compress valuation, yet raised guidance and strong subscriber growth cap the absolute downside and leave room for short-term bounces.